EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 (Novembre 2023) Hors série n° 1 Med Sci (Paris), 39 (2023) 37-46 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 39, Novembre 2023
Les Cahiers de Myologie
Page(s) 37 - 46
Section Mises au point
DOI https://doi.org/10.1051/medsci/2023133
Publié en ligne 17 novembre 2023
  1. Schwartz O, Jampel RS. Congenital blepharophimosis associated with a unique generalized myopathy. Arch Ophthal 1962 ; 68 : 52–57. [CrossRef] [PubMed] [Google Scholar]
  2. Catel W. Differentialdiagnostiche Symptomatologie von Krankheiten des Kinderalters. Stuttgart : George Thieme Ed, 1951 : 48–52. [Google Scholar]
  3. Aberfeld DC, Hinterbuchner LP, Schneider M. Myotonia, dwarfism, diffuse bone disease and unusual ocular and facial abnormalities (a new syndrome). Brain 1965 ; 88 : 313–322. [CrossRef] [PubMed] [Google Scholar]
  4. Huttenlocher PR, Landwirth J, Hanson V, et al. Osteo-chondro-muscular dystrophy. A disorder manifested by multiple skeletal deformities, myotonia, and dystrophic changes in muscle. Pediatrics 1969 ; 44 : 945–958. [CrossRef] [PubMed] [Google Scholar]
  5. Mereu TR, Porter IH, Hug G. Myotonia, shortness of stature, and hip dysplasia. Am J Dis Child 1969 ; 117 : 470–478. [CrossRef] [PubMed] [Google Scholar]
  6. Aberfeld DC, Namba T, Vye MV, et al. Chondrodystrophic myotonia: report of two cases: myotonic dwarfism, diffuse bone disease, and unusual ocular and facial abnormalities. Arch Neurol 1970 ; 22 : 455–462. [CrossRef] [PubMed] [Google Scholar]
  7. Aberfeld DC. Chondrodystrophic myotonia versus Schwartz-Jampel syndrome (Letter). Ann Neurol 1979 ; 5 : 210. [CrossRef] [PubMed] [Google Scholar]
  8. Beighton P.. The Schwartz syndrome in southern Africa. Clin Genet 1973 ; 4 : 548–555. [CrossRef] [PubMed] [Google Scholar]
  9. Fowler WM, Layzer RB, Taylor RG, et al. The Schwartz-Jampel syndrome: its clinical, physiological and histological expressions. J Neurol Sci 1974 ; 22 : 127–146. [CrossRef] [PubMed] [Google Scholar]
  10. van Huffelen AC, Gabreels FJM, van Luypen-van den Horst JS, et al. Chondrodystrophic myotonia: a report of two unrelated Dutch patients. Neuropadiatrie 1974 ; 5 : 71–90. [CrossRef] [Google Scholar]
  11. Pavone L, Mollica F, Grasso A, et al. Schwartz-Jampel syndrome in two daughters of first cousins. J Neurol Neurosurg Psychiat 1978 ; 41 : 161–169. [CrossRef] [PubMed] [Google Scholar]
  12. Cao A, Cianchetti C, Calisti L, et al. Schwartz-Jampel syndrome: clinical electrophysiological and histopathological study of a severe variant. J Neurol Sci 1978 ; 35 : 175–187. [CrossRef] [PubMed] [Google Scholar]
  13. Scaff M, Mendonca LIZ, Levy JA, et al. Chondrodystrophic myotonia: electromyographic and cardiac features of a case. Acta Neurol Scand 1979 ; 60 : 243–249. [Google Scholar]
  14. Edwards WC, Root AW. Chondrodystrophic myotonia (Schwartz-Jampel syndrome): report of a new case and follow-up of patients initially reported in 1969. Am J Med Genet 1982 ; 13 : 51–56. [CrossRef] [PubMed] [Google Scholar]
  15. Moodley M, Moosa A. Chondrodystrophic myotonia (Schwartz-Jampel syndrome) in South African children. Neuropediatrics 1990 ; 21 : 206–210. [CrossRef] [PubMed] [Google Scholar]
  16. Viljoen D, Beighton P. Schwartz-Jampel syndrome (chondrodystrophic myotonia). J Med Genet 1992 ; 29 : 58–62. [CrossRef] [PubMed] [Google Scholar]
  17. Pinto-Escalante D, Ceballos-Quintal JM, Canto-Herrera J. Identical twins with the classical form of Schwartz-Jampel syndrome. Clin Dysmorph 1997 ; 6 : 45–49. [Google Scholar]
  18. Pascuzzi RM, Gratianne R, Azzarelli B, et al. Schwartz-Jampel syndrome with dominant inheritance. Muscle Nerve 1990 ; 13 : 1152–1163. [CrossRef] [PubMed] [Google Scholar]
  19. Nicole S, Ben Hamida C, Beighton P, et al. Localization of the Schwartz-Jampel syndrome (SJS) locus to chromosome 1p34-p36.1 by homozygosity mapping. Hum Mol Genet 1995 ; 4 : 1633–1636. [CrossRef] [PubMed] [Google Scholar]
  20. Giedion A, Boltshauser E, Briner J, et al. Heterogeneity in Schwartz-Jampel chondrodystrophic myotonia. Eur J Pediat 1997 ; 156 : 214–223. [CrossRef] [PubMed] [Google Scholar]
  21. Nicole S, Davoine CS, Topaloglu H, et al. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet 2000 ; 26 : 480–483. [CrossRef] [PubMed] [Google Scholar]
  22. Arikawa-Hirasawa E, Le AH, Nishino I, et al. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet 2002 ; 70 : 1368–1375. [CrossRef] [PubMed] [Google Scholar]
  23. Dagoneau N, Scheffer D, Huber C, et al. Null leukemia inhibitory factor receptor (LIFR) mutations in Stüve-Wiedemann/Schwartz-Jampel Type 2 syndrome. Am J Hum Genet 2004 ; 74 : 298–305. [CrossRef] [PubMed] [Google Scholar]
  24. Arya R, Sharma S, Gupta N, et al. Schwartz Jampel syndrome in children. J Clin Neurosci 2013 ; 220 : 313–317. [CrossRef] [PubMed] [Google Scholar]
  25. Bastola P.Schwartz-Jampel syndrome. Kathmandu Univ Med J 2010 ; 8 : 348–351. [Google Scholar]
  26. Padmanabha H, Suthar R, Sankhyan N, et al. Stiffness, facial dysmorphism, and skeletal abnormalities: Schwartz-Jampel syndrome 1A. J Pediatr 2018 ; 200 : 286.e1. [CrossRef] [PubMed] [Google Scholar]
  27. Ferrannini E, Perniola T, Krajewska G, et al. Schwartz-Jampel syndrome with autosomal-dominant inheritance. Eur Neurol 1982 ; 21 : 137–146. [CrossRef] [PubMed] [Google Scholar]
  28. Spaans F.. Schwartz-Jampel syndrome with dominant inheritance (Letter). Muscle Nerve 1991 ; 14 : 1142. [PubMed] [Google Scholar]
  29. Iwata S, Ito M, Nakata T, et al. A missense mutation in domain III in HSPG2 in Schwartz-Jampel syndrome compromises secretion of perlecan into the extracellular space. Neuromuscul Disord 2015 ; 25 : 667–671. [CrossRef] [PubMed] [Google Scholar]
  30. Das Bhowmik A, Dalal A, Matta D, et al. Identification of a novel splice site HSPG2 mutation and prenatal diagnosis in Schwartz Jampel Syndrome type 1 using whole exome sequencing. Neuromuscul Disord 2016; 26 : 809–14. [CrossRef] [PubMed] [Google Scholar]
  31. Yan W, Dai J, Shi D, et al. Novel HSPG2 mutations causing Schwartz-Jampel syndrome type 1 in a Chinese family: a case report. Mol Med Rep 2018 ; 18 : 1761–1765. [PubMed] [Google Scholar]
  32. Stum M, Davoine CS, Vicart S, et al. Spectrum of HSPG2 (perlecan) mutations in patients with Schwartz-Jampel syndrome. Hum Mutat 2006 ; 27 : 1082–1091. [CrossRef] [PubMed] [Google Scholar]
  33. Martinez JR, Dhawan A, Farach-Carson MC. Modular Proteoglycan Perlecan/HSPG2: mutations, phenotypes, and functions. Genes 2018 ; 9 : 556. [CrossRef] [PubMed] [Google Scholar]
  34. Kallunki P, Eddy RL, Byers MG, et al. Cloning of human heparan sulfate proteoglycan core protein, assignment of the gene (HSPG2) to 1p36.1-p35 and identification of a BamHI restriction fragment length polymorphism. Genomics 1991 ; 11 : 389–396. [CrossRef] [PubMed] [Google Scholar]
  35. Noonan DM, Fulle A, Valente P, et al. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 1991 ; 266 : 22939–22947. [CrossRef] [PubMed] [Google Scholar]
  36. Graham LD, Whitelock JM, Underwood PA. Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Biochem Biophys Res Commun 1999 ; 256 : 542–548. [CrossRef] [Google Scholar]
  37. Xu Z, Ichikawa N, Kosaki K, et al. Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition. Matrix Biol 2010 ; 29 : 461–470. [CrossRef] [PubMed] [Google Scholar]
  38. Ning L, Xu Z, Furuya N, et al. Perlecan inhibits autophagy to maintain muscle homeostasis in mouse soleus muscle. Matrix Biol 2015 ; 48 : 26–35. [CrossRef] [PubMed] [Google Scholar]
  39. Pei S, Parthasarathy S, Parajuli A, et al. Perlecan/Hspg2 deficiency impairs bone’s calcium signaling and associated transcriptome in response to mechanical loading. Bone 2020; 131 : 115078. [CrossRef] [PubMed] [Google Scholar]
  40. Bauche S, Boerio D, Davoine CS, et al. Peripheral nerve hyperexcitability with preterminal nerve and neuromuscular junction remodeling is a hallmark of Schwartz-Jampel syndrome. Neuromuscul Disord 2013 ; 23 : 998–1009. [CrossRef] [PubMed] [Google Scholar]
  41. Arikawa-Hirasawa E, Wilcox WR, Yamada Y. Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development. Am J Med Genet 2001 ; 106 : 254–257. [CrossRef] [PubMed] [Google Scholar]
  42. Arikawa-Hirasawa E, Rossi SG, et al. Absence of acetylcholinesterase at the neuromuscular junctions of perlecan-null mice. Nat Neurosci 2002 ; 5 : 119–123. [CrossRef] [PubMed] [Google Scholar]
  43. Nicole S, Topaloglu H, Fontaine B. 102nd ENMC International Workshop on Schwartz-Jampel syndrome, 14–16 December, 2001, Naarden. The Netherlands. Neuromuscul Disord 2003 ; 13 : 347–351. [CrossRef] [Google Scholar]
  44. Spaans F, Wagenmakers A, Saris W, et al. Procainamide therapy, physical performance and energy expenditure in the Schwartz-Jampel syndrome. Neuromuscul Disord 1991 ; 1 : 371–374. [CrossRef] [PubMed] [Google Scholar]
  45. Gurbuz G, Albayrak HM. Schwartz Jampel syndrome responding positively to carbamazepine therapy: a case report and a novel mutation. Turk J Pediatr 2019 ; 61 : 967–970. [CrossRef] [PubMed] [Google Scholar]
  46. Yamashita Y, Nakada S, Nakamura K, et al. Evaluation of human-induced pluripotent stem cells derived from a patient with Schwartz-Jampel syndrome revealed distinct hyperexcitability in the skeletal muscles. Biomedicines 2023; 11 : 814. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.